Zain Husain

Radiation Oncologist
Retweet is not an endorsement

[Sana Karam, MD, PhD @KaramLab]

FINALLY, OUT: Our Trial Results with Neoadjuvant Durvalumab + SBRT in locally advanced HPV unrelated HNSCC. https://t.co/S1JcuTh3Go or https://t.co/OQqPckUk7u.

[Neil D. Gross, MD, FACS @DrNeilGross]

Grateful for the patients, their families, @Regeneron and all the investigators involved in this confirmatory multicenter phase II trial of neoadjuvant #immunotherapy in resectable #CSCC @MDAndersonNews @TheMillerLab @evanlipson https://t.co/ulvLFgwFQM

[Nauman Malik (نعمان) @naummalik]

Was fun writing this for September's @IJROBP Gray Zone case; an interesting HPV+ OPC question by @baileynelson92 & Dr. Takiar. A recurring scenario in the TORS era - even as our understanding evolves, Qs remain.

Thanks to @ZHusainMD for the guidance!

https://t.co/m5qNWHfFg3

[arjun sahgal @SahgalArjun]

Big congrats to the head and neck @Sunnybrook team treating our first head and neck cancer patient on the @Elekta Unity MR Linac. Major step to adaptive radiation in this challenge disease.

[Zain Husain @ZHusainMD]

New cancer diagnostics will save lives, writes Siddhartha Mukherjee, but they risk turning all of us into anxious ‘previvors.’ https://t.co/vZII4T9NNf

[University of Toronto @UofT]

Researchers from @UofTMedicine & @Sunnybrook researchers deliver ultrasound-guided cancer therapy to the brain #UofT 🧠 https://t.co/5J8EnXftVc

[Clinical Cancer Research @CCR_AACR]

Neoadjuvant #immunotherapy in locoregionally advanced, resectable cutaneous #SquamousCellCarcinoma of the Head and Neck is safe and induces a high pathologic response rate. https://t.co/ZvnsVhaVyJ
@FayeJohnso @PaulGidleyMD @DrNeilGross

[Corey Foster @corey_c_foster]

A must-read, first-hand account of dietary struggles during RT for head and neck cancer. #foodislife #hnsm https://t.co/m47svbQRHX

[arjun sahgal @SahgalArjun]

Thank you to @CDNCancerTrials, all my co investigators, @TROGfightcancer, @Sunnybrook, @UofTSpine, @UofTDRO and @TheLancetOncol
as sc24 is out and shows 24Gy in 2 sbrt fractions is superior to conv radiation for selected painful spinal metastases

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Delighted to share results from our neoadjuvant immunoradiotherapy trial in #HeadAndNeckCancer, out in @jitcancer
8Gyx3 to GTV + Nivo prior to surgery=
pCR=67%
MPR (<10% viable rumor cells)=86%
Clin to path downstaging=90%
No adjuvant tx
@ChilesResearch
https://t.co/xfeQhWbWT0

[ECOG-ACRIN Cancer Research Group @eaonc]

During #OralHeadandNeckCancerAwareness Month we are highlighting our head and neck #cancertrials. #EA3161 is testing immunotherapy versus observation in #HPV positive throat cancer. Learn more: https://t.co/74f3pmB38T #HNCA #HNCSM Cc: @DrNabilSaba, @BarbaraBurtness

[Sean McBride @seanmmcbride]

Outstanding article on how difficult operational changes can be in healthcare. https://t.co/Ni2z15hkEd

[C. Jillian Tsai, MD, PhD @CJTsaiMDPhD]

🚨 In this seminal RCT done by @imrtlee @MSK_RadOnc @sloan_kettering, the addition of Avelumab to SOC chemoRT in PDL-1 unselected LA-HNSCC did not prolong PFS, the study's primary endpoint.

https://t.co/XYT5ffVaog

[Zain Husain @ZHusainMD]

@SprakerMDPhD @SchaubMD @CancerConnector @ShaunaRadOnc yeah so limitations of all databases, but for rare diseases not much choice. we chose to train on seer so we could also see that the CSS curves separated and then validate in NCDB since there's only OS data there.  RPA seems to validate nicely.

[Zain Husain @ZHusainMD]

shout out to @NickLeeMD for his hard work and dedication. new paper suggesting a new stage grouping system for HN sarcoma https://t.co/s4g8IkvO2f @CShahMD @DrTonyEskander @HenryParkMD @JAMRadOnc

[Nadeem Riaz @xrtGenomics]

Out now in @JNCI_now (https://t.co/rCHsSXxnef)! @sloan_kettering H&N team’s work on Precision Radiotherapy for HPV+ HNSCC: **30Gy** for definitive treatment! Spear-headed by @imrtlee & Eric Sherman, & and an all-star translational cast (JRF, SNP, TC, & more). #radonc #hncsm (1/N)

[ICES @ICESOntario]

New @ICESOntario and @Sunnybrook study in @ASCO shows nearly 1 in 5 patients with head and neck cancer visit the ED within 14 days of reporting high symptom burden @chrisnoelmd @rinku_rinkurani @DrNCoburn @DrTonyEskander
https://t.co/nVGeUuuCrm

[arjun sahgal @SahgalArjun]

Congrats to Ian Poon and the CORE international group pooling 1033 OM patients treated with SBRT so we can further understand outcomes in this potentially curable population

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Very pleased to share the results of our RCT on consolidation RT in metastatic NPC changing the paradigm of how we think of treating metastatic disease and altering disease trajectory! #nasopharyngealcarcinoma #radiotherapy #metastasis @JAMAOnc

[Zain Husain @ZHusainMD]

my fave part of red j. was fun to respond w/ @BarbaraBurtness and always fun to see how others think https://t.co/66Vipi18vI